Entering text into the input field will update the search result below

Checking Back In On Cara Therapeutics

Nov. 01, 2021 2:11 PM ETCara Therapeutics, Inc. (CARA) Stock2 Comments



ktsimage/iStock via Getty Images

Numbing the pain for a while will make it worse when you finally feel it." - J.K. Rowling

News flow seems to have picked up around Cara Therapeutics (NASDAQ:CARA) of late. The company also got a key

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

Bret Jensen profile picture

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.

Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CARA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum, and Insiders Forum

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (2)

Bret Jensen profile picture
Cara Therapeutics (NASDAQ:CARA) said its licensing partner Maruishi Pharmaceutical submitted a new drug application (NDA) in Japan for approval of Korsuva (difelikefalin) to treat (itching) pruritus in hemodialysis patients.
The NDA is backed by data from a phase 3 trial in Japan, the company said in a Sept. 28 press release.
The Insiders Forum profile picture
Biopharmaceutical company Cara Therapeutics (NASDAQ:CARA) has appointed Christopher Posner as its new President and CEO, effective November 9, 2021.
Posner, a current member of Cara Therapeutics' Board of Directors, will succeed Derek Chalmers, who will transition to a Senior Advisor role. Prior to this appointment, Posner held the President and CEO role at LEO Pharma.
CARA +3.44% pre-market
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About CARA Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CARA

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.